New Jersey 2022-2023 Regular Session

New Jersey Assembly Bill A5066

Introduced
1/19/23  

Caption

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

Impact

The impact of A5066 on state laws is significant, as it formalizes the procedure for managing hypoglycemic episodes within schools. With the increase in diabetes diagnoses among children, it is essential for schools to have ready-to-use emergency treatments accessible at all times. This legislation not only facilitates a proactive approach to student health and safety but also provides legal protections for school employees administering the glucagon, ensuring they cannot be held liable for good faith actions taken in emergency situations.

Context

The bill comes at a time when the prevalence of diabetes, particularly among children, is rising, highlighting the need for effective management strategies in schools. It acknowledges the necessity of having medical interventions ready and expands the scope of care that schools are expected to provide. The New Jersey legislature's move toward prioritizing student health through this bill reflects an increasing recognition of the importance of diabetes care in educational settings.

Summary

Assembly Bill A5066 concerns the administration of ready-to-use undesignated glucagon rescue therapy in public schools in New Jersey. The bill mandates that school districts must obtain a standing order for ready-to-use glucagon, which can be administered by authorized school employees to students experiencing severe hypoglycemia. This legislation is particularly important for students with diabetes, ensuring timely access to treatment during potential medical emergencies. The bill establishes guidelines for schools and defines roles for school employees and healthcare professionals concerning the management of diabetes in the school environment.

Contention

A notable point of contention surrounding A5066 may involve concerns regarding the training and responsibilities of school staff in administering glucagon. Critics may voice concerns over whether all school personnel are adequately trained to handle such medical emergencies effectively. Additionally, there may be discussions about ensuring that parents and guardians are engaged in developing individualized emergency health care plans for their children, ensuring that protocols align with specific medical needs and responses.

Companion Bills

No companion bills found.

Similar Bills

NJ A1882

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

DC B25-0226

Access to Emergency Albuterol and Glucagon Amendment Act of 2023 (now known as "Access to Emergency Medications Amendment Act of 2023")

WV SB195

Glucagon for Schools Act

FL H0597

Diabetes Management in Schools

KY HB438

AN ACT relating to undesignated glucagon.

KY HB295

AN ACT relating to undesignated glucagon.

ME LD867

An Act Regarding Undesignated Ready-to-use Glucagon Rescue Therapies in Schools

KY HB174

AN ACT relating to undesignated glucagon.